ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $91.00 million. The enterprise value is $94.59 million.
| Market Cap | 91.00M |
| Enterprise Value | 94.59M |
Important Dates
The last earnings date was Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 9.08 million shares outstanding. The number of shares has increased by 3.49% in one year.
| Current Share Class | 9.08M |
| Shares Outstanding | 9.08M |
| Shares Change (YoY) | +3.49% |
| Shares Change (QoQ) | +1.58% |
| Owned by Insiders (%) | 28.05% |
| Owned by Institutions (%) | 18.73% |
| Float | 6.03M |
Valuation Ratios
The trailing PE ratio is 134.37.
| PE Ratio | 134.37 |
| Forward PE | n/a |
| PS Ratio | 2.97 |
| Forward PS | n/a |
| PB Ratio | 2.90 |
| P/TBV Ratio | 2.91 |
| P/FCF Ratio | 21.59 |
| P/OCF Ratio | 15.45 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.42, with an EV/FCF ratio of 22.44.
| EV / Earnings | 120.13 |
| EV / Sales | 3.08 |
| EV / EBITDA | 13.42 |
| EV / EBIT | 20.27 |
| EV / FCF | 22.44 |
Financial Position
The company has a current ratio of 4.75, with a Debt / Equity ratio of 0.40.
| Current Ratio | 4.75 |
| Quick Ratio | 2.65 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | 1.66 |
| Debt / FCF | 2.95 |
| Interest Coverage | 10.70 |
Financial Efficiency
Return on equity (ROE) is 2.57% and return on invested capital (ROIC) is 12.29%.
| Return on Equity (ROE) | 2.57% |
| Return on Assets (ROA) | 6.25% |
| Return on Invested Capital (ROIC) | 12.29% |
| Return on Capital Employed (ROCE) | 11.06% |
| Weighted Average Cost of Capital (WACC) | 6.89% |
| Revenue Per Employee | $420,213 |
| Profits Per Employee | $10,786 |
| Employee Count | 73 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 2.11 |
Taxes
In the past 12 months, ImmuCell has paid $66,233 in taxes.
| Income Tax | 66,233 |
| Effective Tax Rate | 7.76% |
Stock Price Statistics
The stock price has increased by +64.67% in the last 52 weeks. The beta is 0.57, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +64.67% |
| 50-Day Moving Average | 10.54 |
| 200-Day Moving Average | 7.87 |
| Relative Strength Index (RSI) | 41.73 |
| Average Volume (20 Days) | 34,234 |
Short Selling Information
The latest short interest is 17,605, so 0.19% of the outstanding shares have been sold short.
| Short Interest | 17,605 |
| Short Previous Month | 14,048 |
| Short % of Shares Out | 0.19% |
| Short % of Float | 0.29% |
| Short Ratio (days to cover) | 0.56 |
Income Statement
In the last 12 months, ImmuCell had revenue of $30.68 million and earned $787,373 in profits. Earnings per share was $0.07.
| Revenue | 30.68M |
| Gross Profit | 12.37M |
| Operating Income | 4.67M |
| Pretax Income | 853,606 |
| Net Income | 787,373 |
| EBITDA | 7.05M |
| EBIT | 4.67M |
| Earnings Per Share (EPS) | $0.07 |
Balance Sheet
The company has $8.86 million in cash and $12.45 million in debt, with a net cash position of -$3.59 million or -$0.39 per share.
| Cash & Cash Equivalents | 8.86M |
| Total Debt | 12.45M |
| Net Cash | -3.59M |
| Net Cash Per Share | -$0.39 |
| Equity (Book Value) | 31.37M |
| Book Value Per Share | 3.45 |
| Working Capital | 16.64M |
Cash Flow
In the last 12 months, operating cash flow was $5.89 million and capital expenditures -$1.68 million, giving a free cash flow of $4.21 million.
| Operating Cash Flow | 5.89M |
| Capital Expenditures | -1.68M |
| Depreciation & Amortization | 2.38M |
| Net Borrowing | -1.52M |
| Free Cash Flow | 4.21M |
| FCF Per Share | $0.46 |
Margins
Gross margin is 40.32%, with operating and profit margins of 15.21% and 2.57%.
| Gross Margin | 40.32% |
| Operating Margin | 15.21% |
| Pretax Margin | 2.78% |
| Profit Margin | 2.57% |
| EBITDA Margin | 22.98% |
| EBIT Margin | 15.21% |
| FCF Margin | 13.74% |
Dividends & Yields
ImmuCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.49% |
| Shareholder Yield | -3.49% |
| Earnings Yield | 0.87% |
| FCF Yield | 4.63% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmuCell has an Altman Z-Score of 3.51 and a Piotroski F-Score of 8.
| Altman Z-Score | 3.51 |
| Piotroski F-Score | 8 |